Applied Imaging subject to Nasdaq-delisting
This article was originally published in Clinica
Executive Summary
Applied Imaging could face being delisted from Nasdaq after failing to file its quarterly report for the period ended September 30 2004 with the US Securities and Exchange Commission. The company's appeal against the delisting is under review by the Nasdaq Listing Qualifications Panel. Until the final determination, the date of which is not known, the company's shares will be traded under an amended trading symbol.
You may also be interested in...
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.